share_log

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

先天药物用于检测复发/难治性外周T细胞淋巴瘤患者的Lacutamab
Benzinga Real-time News ·  2021/02/09 20:19
  • Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit additional patients. The company expects to present the preliminary data from this cohort at a scientific meeting this year. The study is expected to recruit up to 150 patients.
  • Recruitment in cohort 3 is ongoing, evaluating lacutamab as monotherapy in KIR3DL2 non-expressing mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma.
  • The company also plans to initiate two parallel trials to evaluate lacutamab in KIR3DL2-expressing patients with relapsed/refractory peripheral T-cell lymphoma, including a Company-sponsored Phase 1b trial to evaluate lacutamab as monotherapy in KIR3DL2-expressing patients with relapsed PTCL, and an investigator-sponsored trial to evaluate lacutamab in combination with chemotherapy GEMOX, versus GEMOX alone in KIR3DL2-expressing relapsed/refractory patients.
  • Webcast and conference call is scheduled for 8:00 a.m. ET today.
  • Price Action: IPHA shares closed 5.5% higher at $4.63 on Monday.
  • 先天制药公司(Innate Pharma SA)(纳斯达克：IPHA)正在进行TELLOMAK第二阶段试验，评估lacutamab已经达到了进入第二阶段所需的预定反应数量，从而允许Innate招募更多的患者。该公司预计将在今年的一次科学会议上公布这一队列的初步数据。这项研究预计将招募多达150名患者。
  • 在队列3中的招募正在进行中，评估lacutamab作为KIR3DL2非表达真菌样肉芽肿的单一疗法，这是一种最常见的血癌类型，称为皮肤T细胞淋巴瘤。
  • 该公司还计划启动两个平行试验为了评估lacutamab在表达KIR3DL2的复发性/难治性外周T细胞淋巴瘤患者中的作用，包括一项由公司赞助的1b期试验，目的是评估lacutamab在表达KIR3DL2的复发性PTCL患者中作为单一疗法的作用；以及一项由研究人员赞助的试验，评估lacutamab联合化疗GEMOX，以及在表达KIR3DL2的复发/难治性患者中仅使用GEMOX的疗效。
  • 网络直播和电话会议安排在上午8：00。东部时间今天。
  • 价格行动：IPHA股价周一收高5.5%，报4.63美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发